ALMU: Klamkin Receives Options and RSUs, Executes 10b5-1 Sale
Rhea-AI Filing Summary
Jonathan Klamkin, Aeluma, Inc. CEO and director, reported option and restricted stock unit awards and a planned sale of common stock. The report shows a bonus grant of 6,253 stock options exercisable at $16.37 and 2,403 restricted stock units (RSUs) that vested immediately, each RSU converting into one share on settlement. Following those awards, the reporting person sold 150,000 shares under a Rule 10b5-1 trading plan at a weighted average price of $18.8487 per share. Beneficial ownership decreased from 1,629,398 shares to 1,479,398 shares after the sale.
Positive
- Board-approved equity bonus (6,253 options and 2,403 RSUs) aligns executive compensation with shareholder interests
- Sale executed under a Rule 10b5-1 plan, providing an affirmative defense and reducing regulatory risk
Negative
- Beneficial ownership decreased by 150,000 shares, reducing the reporting person's stake from 1,629,398 to 1,479,398 shares
- Immediate vesting of awards may increase near-term potential dilution and could be seen as significant executive compensation
Insights
TL;DR: Executive received immediate equity awards while executing a pre-established sale plan; overall ownership fell by 150,000 shares.
The immediate vesting of 6,253 options and 2,403 RSUs represents a compensation event that increases potential future dilution but also aligns management pay with shareholder outcomes because awards are equity-based. The 150,000-share sale was conducted pursuant to a Rule 10b5-1 plan and executed at a weighted average price of $18.8487, which reduces the reporting person's current share count to 1,479,398. These actions are routine for executive compensation and liquidity management and do not by themselves indicate a change in company fundamentals.
TL;DR: Board-approved bonus vested immediately; sale followed a 10b5-1 plan—governance appears to follow accepted procedures.
The disclosure notes the bonus (board-approved) and immediate vesting of equity awards, which should be documented in compensation minutes. The sale was executed under a previously adopted 10b5-1 trading plan (May 14, 2025), providing an affirmative defense to insider trading claims. From a governance perspective, the form properly reports the awards and the planned sale, consistent with transparency and established insider trading controls.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 150,000 | $18.8487 | $2.83M |
| Other | Stock Option | 6,253 | $16.37 | $102K |
| Other | Common Stock | 2,403 | $16.37 | $39K |
Footnotes (1)
- Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the contingent right to receive one share of Common Stock of the Issuer upon vesting of the RSU. The RSUs and the Stock Options were granted to the Reporting Person as a bonus and vested immediately (the "Bonus"). The Bonus was approved by the Issuer's Board of Directors. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025. These shares were sold in multiple transactions at prices ranging from $18.84520 to $18.85230. The price reported above reflects the weighted average sale price. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price.